A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141

Carcinoma of the head and neck accounts for ≥600,000 new cases and >300,000 deaths each year globally [1]. In Japan, the incidence of invasive oral, pharynx, and larynx cancers was estimated at 24,557 in 2012 [2]. The incidence of carcinoma of the head and neck is also increasing. In South Korea, the incidence of all carcinomas of the head and neck has increased since 1998, except for laryngeal cancer [3]. In Taiwan, among solid cancers, oropharyngeal cancer had the fourth greatest increase in incidence from 2002 to 2012, with an average annual percentage increase of 5% [4].

http://ift.tt/2jGFesp